18 November 2024
18 November 2024
Plozasiran specifically targets and reduce the production of APOC3, thereby reducing triglyceride levels and lowering the associated health risks of FCS.
Revenue for the mpox vaccine is down compared to last year however its travel vaccine business grew by 21%.
AC Immune’s Phase II trial showed an increase in anti-a-syn antibodies following treatment with the Parkinson’s disease vaccine like therapy.
Like monoclonal antibodies, lerodalcibep binds to PCSK9, blocking its interaction with LDL receptors (LDLR).
The approval is based on the Phase I/II AUGMENT-101 trial, which included 104 patients with acute leukaemia.
The CHMP's opinion is based on the Phase III, open-label CheckMate -8HW trial.
The decision in Europe follows an approval granted by the US Food and Drug Administration (FDA) in March this year.
The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
